EUROPEAN COMMITTEE FOR TREATMENT AND RESEARCH IN..

9th Joint ECTRIMS-ACTRIMS meeting

 

11–13 October 2023 Milan
Close
N. Poster
Poster title
Applicant name
Status
  1-P Inclusion of optic neuritis improves the performance of McDonald 2017 criteria in Hispanic people with suspected multiple sclerosis Lilyana Amezcua Received Received
  2-P How Well Do Junior Neurology Residents Recognize Multiple Sclerosis? Analysis of the Close the Loop Resident Clinical Acumen Project Claudia Zbrzeski Received Received
  3-P Clinical and radiological phenotype of adult-onset neurogenetic diseases mimicking multiple sclerosis: a multinational observational study Gabrielle Macaron Received Received
  18-P Humoral signatures of MOG-antibody associated disease Jan Lünemann Received Received
  19-P Predictors of the risk of relapse in children with MOGAD Akash Virupakshaiah Received Received
  21-P Clinical predictors of outcomes in pediatric myelin oligodendrocyte glycoprotein antibody disease Alexandra Kornbluh Received Received
  23-P Late-onset MOGAD : a French multicenter retrospective study Julie Pique Received Received
  40-P Relationship between brain reserve and timing of clinical onset in Multiple Sclerosis Maria Petracca Received Received
  42-P Patterns and Predictors of Conversion from Relapsing-Remitting to Secondary Progressive MS: A Longitudinal Study Using the Danish Multiple Sclerosis Registry Melinda Magyari Received Received
  43-P Clinic-level quality of care affects patient outcomes in relapse-onset MS Anna He Received Received
  44-P Racial differences in disability and treatment of relapsing MS in a universal healthcare context Anna He Received Received
  45-P Disease modifying therapy use among people living with multiple sclerosis based on socioeconomic status and urban/rural residence: a retrospective cohort study from Alberta, Canada Erin Balcom Received Received
  47-P Epidemiology of Relapsing Remitting Multiple Sclerosis in Chile between 2010 and 2021 Lorna Galleguillos Received Received
  54-P Prognostic factors of Disease Activity in Newly-diagnosed Teriflunomide Treated Patients with Multiple Sclerosis - A Nationwide Danish Study Mie Reith Mahler Received Received
  58-P Sex-related Differences in Treatment of Multiple Sclerosis - a retrospective analysis of the Austrian National MS registry Harald Hegen Received Received
  62-P Evidence of disease activity during pregnancy and post-partum in MS patients treated with high-efficacy therapies: a monocentric retrospective study Oussama Sahloul Received Received
  71-P Performance of gold-standard cognitive measures for detecting change over time: Longitudinal analysis of retrospective data Victoria Leavitt Received Received
  78-P Linking fatigue trajectories in relapsing-remitting multiple sclerosis to incidence of psychiatric comorbidities and productivity loss in the years following initiation of disease modulating therapy Simon Englund Received Received
  80-P The Next Generation Learning Health System for Multiple Sclerosis (NextGen MS): Study design, demographics, and analysis of system-level variation in baseline characteristics. Falguni Mehta Received Received
  87-P Patient-reported factors impacting well-being in individuals with multiple sclerosis - a cross-sectional study Sabrina Islamoska Received Received
  92-P Uveitis and central nervous system involvement: retrospective follow-up of a cohort of 175 uveitis patients Alexandra Maury Received Received
  93-P Genotype-phenotype correlation in multiple sclerosis: a study of predictive genetic markers for autoimmune comorbidities with an innovavtive approach tolink genomic data with electronic administrative health databases Nadia Barizzone Received Received
  94-P Elevated Incidence and Prevalence of Peripartum Mental Illness in Women with Multiple Sclerosis Ruth Ann Marrie Received Received
  98-P The influence of comorbid depression and anxiety on cognition in people with multiple sclerosis David Freedman Received Received
  99-P Prevalence and patterns of comorbidity in people with multiple sclerosis Marie Lynning Received Received
  109-P PAK1 and E2F1 dysregulation induces a p21-mediated defect of oligodendrocyte differentiation in a cerebral organoid model of multiple sclerosis Nicolas DAVIAUD Received Received
  118-P Meta-analysis for Neurofilament Light Chain (NfL) as Biomarker in Mouse Experimental Autoimmune Encephalomyelitis (EAE) Studies Lakshmi Narendra Bodduluru Received Received
  120-P Investigation of cerebrospinal fluid antibody specificity in primary progressive MS Jerry Lin Received Received
  140-P Age-associated change in Th17 and cytokine response in Multiple Sclerosis Zongqi Xia Received Received
  150-P Cytomegalovirus in multiple sclerosis patients: how does it interact with the infection by Epstein-Barr virus and human herpesvirus 6A/B? Roberto Alvarez-Lafuente Received Received
  151-P Environmental risk factors in multiple sclerosis. FRAMES study. Roberto Álvarez-Lafuente Received Received
  162-P Ublituximab Reduces Thalamic Volume Loss and New Lesion Formation in Participants of the ULTIMATE I & II Phase 3 Studies Victoria Findlen Received Received
  176-P Disagreement Among Neuroradiologists Detecting Change in Multiple Sclerosis Disease Activity Melissa Karr Received Received
  177-P Interpretable Thalamic Volume Charts in Multiple Sclerosis Melissa Karr Received Received
  179-P Efficacy of Ofatumumab on Microglial Activity and Brain Iron in Patients With Relapsing Forms of Multiple Sclerosis: Results From a 9-Month Study Venkateswarlu Bonala Received Received
  180-P Cortical glial activity is linked with serum GFAP levels and cortical atrophy in multiple sclerosis patients treated with high-efficacy DMTs: a F-18PBR06-PET study Tarun Singhal Received Received
  181-P Brain Age and Quantitative Susceptibility Mapping of Chronic Active Lesions in Relapsing Multiple Sclerosis Lars Skattebl Received Received
  182-P Paramagnetic rim lesions: a longitudinal evaluation with treatment associations Christopher Hemond Received Received
  189-P Early cortical thinning of posterior and temporal regions in relapsing-remitting multiple sclerosis Sarah Levy Received Received
  192-P Contribution of 7T brain MRI to the detection of cortical lesions at the earliest stage of multiple sclerosis. Jean Pelletier Received Received
  203-P Depicting longitudinal MS disease course using lesion parenchymal fraction (LPF): a quantified expression of the topographical model of MS Stephen Krieger Received Received
  209-P Spinal cord microstructural damage measured in recently diagnosed Relapsing Remitting MS patients : prognostic value at 5-year Vivien Caron Received Received
  214-P OCT-based differentiation between MOGAD and MS after the first optic neuritis episode Thivya Pakeerathan Received Received
  219-P Creation and performance of the International MOGAD Diagnostic Criteria Brenda Banwell Received Received
  221-P Highly Sensitive Proteomic Immunoassays to Identify Novel Serum Biomarkers for Multiple Sclerosis Disease Progression in Natalizumab Treated Patients Sjors In t Veld Received Received
  227-P Comparison of Baseline Demographic Specific Reference Ranges for NfL and GFAP Between Serum and Plasma in Healthy Controls KAVITA NAIR Received Received
  232-P Real-World Utilization of a Proteomic Biomarker Panel for Assessing Multiple Sclerosis Disease Activity in an Academic Multiple Sclerosis Clinic with a Diverse Patient Population William Kilgo Received Received
  235-P Serum Biomarkers of Clinical and Radiographic Disease Progression in Multiple Sclerosis Melissa Karr Received Received
  237-P Immune cell subpopulations and serum neurofilament light chain are associated with increased risk of disease worsening in multiple sclerosis Synne Brune-Ingebretsen Received Received
  238-P The Impact of Natalizumab Treatment on Cerebrospinal Fluid Oligoclonal Bands in Multiple Sclerosis Patients Francois Jacques Received Received
  239-P Serum neurofilaments are a reliable biomarker to early detect PML in Multiple Sclerosis patients Antonio Bertolotto Received Received
  252-P Plasma lipidomic profiling by mass spectrometry for Multiple Sclerosis diagnosis and disease activity stratification (LipidMS) Justus Lattau Received Received
  253-P Long-Term Immune Response to COVID-19 Vaccines in Multiple Sclerosis: A Multi-Center Study Sarah Wesley Received Received
  268-P Ultra-high field MRI-derived brain age correlates with cognitive performance in people with multiple sclerosis Francesco La Rosa Received Received
  275-P Phase 2 Efficacy and Safety of Frexalimab: 6-Month Results of a Novel CD40L Inhibitor in Relapsing Multiple Sclerosis Patrick Vermersch Received Received
  276-P Phase III MIRANTIBUS trial: results of 48 weeks treatment with divozilimab versus teriflunomide in relapsing multiple sclerosis. Alexey Boyko Received Received
  277-P Durability of Immune Response to COVID-19 Vaccines in Persons with MS on B-cell Depleting Therapy Rebecca Straus Farber Received Received
  281-P Treatment of six non-active secondary progressive MS patients with nasal anti-CD3 monoclonal antibody (Foralumab): safety, biomarker, and disability outcomes Tanuja Chitnis Received Received
  282-P Phase I trial of faecal microbiota transplantation in MS Bob van Oosten Received Received
  286-P Changes in Immunoglobulin in Patients with Multiple Sclerosis Treated with Anti CD20 Monoclonal Antibodies Brandi Vollmer Received Received
  288-P COVID-19 Outcomes and Seropositivity Rates Following SARS-CoV-2 Vaccine and/or Infection in Ofatumumab-treated RMS Patients: Data from the ALITHIOS Open-label Extension Study Bhavesh Kshirsagar Received Received
  295-P VISIONARY-MS Topline Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis Heidi Beadnall Received Received
  296-P harnessing the endogenous adaptive response to hypoxia-ischemia as a therapy for neurodegeneration in multiple sclerosis Carlos Camara Received Received
  309-P DISCOntinuation of disease-modifying therapies in Multiple Sclerosis (DISCOMS): Primary results of the extension trial John Corboy Received Received
  314-P Endogenous IgG4 Concentration Impacts Natalizumab Arm Exchange and Intact Drug Pharmacokinetics Bradley Messmer Received Received
  315-P ACAPELLA: Hypogammaglobulinemia in Ocrelizumab-Treated Patients, Year Six Data Joshua Katz Received Received
  318-P GA Depot (long-acting IM injection of glatiramer acetate) presents improved safety and tolerability features: results from a multi-national, double-blind, placebo-controlled phase III study in subjects with relapsing forms of Multiple Sclerosis. Ehud Marom Received Received
  320-P Humoral response to Epstein-Barr virus in patients with multiple sclerosis treated with B cell depletion therapy Brit Ellen Rd Received Received
  323-P The role of ganglion cell inner plexiform layer thickness in evaluating the neuroprotective role of phenytoin in the visual pathway Srikirti Kodali Received Received
  325-P Risk of cardiovascular disease in patients treated with fingolimod compared to natalizumab: A nationwide cohort study in Denmark Elisabeth Framke Received Received
  331-P Stopping Fingolimod is associated with a high risk of radiological disease reactivation Rolf Holm Received Received
  338-P The use of pragmatic randomized trials in Multiple Sclerosis: a systematic overview perrine Janiaud Received Received
  339-P Patient preference and time allocation assosiated with transition from intravenous to subcutaneus administration of natalizumab in patients with relapsing remitting MS - a questionnaire study Anna Almroth Received Received
  345-P Disparities in DMT Treatment Access: Demographic and neurocognitive differences between MS patients currently treated versus not treated with disease-modifying therapies Victoria Leavitt Received Received
  350-P Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis Scott Newsome Received Received
  359-P Efficacy and safety of diroximel fumarate compared with interferon beta-1a in relapsing-remitting multiple sclerosis: Propensity Score Matching Analysis of Phase 3 Data from EVOLVE-MS-1 and DECIDE Christin Henning Received Received
  360-P Incidence of new menstrual cycle disorders in a cohort of 120 women with multiple sclerosis treated with cladribine: a single-arm oberservational multi-center cohort study Birte Elias-Hamp Received Received
  374-P Increased risk of cancer in multiple sclerosis: a birth cohort study in Wales using routinely collected data Madeeha Khan Received Received
  375-P Similarities in Brain Damage Across the Spectrum of Multiple Sclerosis Bhavesh Kshirsagar Received Received
  379-P Validation of the 2023 diagnostic criteria for MOGAD at a tertiary care center Linda Nguyen Received Received
  383-P Is Fatigue in MS the same one manifesting as Wearing-off Symptom in Natalizumab treated patients? Giuseppe Magro Received Received
  395-P Trait Conscientiousness and Multiple Sclerosis: Predicting Disease Progression and Assessing the Effects of an App-Supported Behavioral Intervention Michael Jaworski Received Received
  417-P Comparison of Vision-Related Quality of Life in AQP4 NMOSD and MOGAD Adnan A. Gassan Received Received
  418-P Myelin Oligodendrocyte Glycoprotein (MOG) Antibody Disease and MOG/AQP4 Testing Landscape in Canada Jodie Burton Received Received
  421-P The Neutrophil-to-lymphocyte ratio is a marker of acute inflammation but does not predict relapses or disease severity in a UK cohort of people with MOGAD and NMOSD Radu Tanasescu Received Received
  423-P Assessing the performance of cell based assays for MOGAD in the real world setting of a resource poor region - Impact of the international MOGAD diagnostic criteria Lekha Pandit Received Received
  424-P Depression and Cognition in Multiple Sclerosis: Longitudinal Evidence of a Specific Link to Executive Control Jordyn Anderson Received Received
  435-P Assessing likelihood of secondary progressive multiple sclerosis in Sweden and Denmark: A federated learning analysis unveiling modestly higher odds in Sweden Lars Forsberg Received Received
  443-P The impact of changing diagnostic criteria on disability in a 25-year Brazilian cohort of multiple sclerosis Felipe Menezes Received Received
  444-P Anticonvulsant & gabapentinoid pharmacotherapy in the multiple sclerosis prodrome: a population-based matched cohort study Himali Bergeron-Vitez Received Received
  447-P Migraine in the multiple sclerosis prodrome. A prospective nationwide cohort study Karine Eid Received Received
  449-P Changing age of multiple sclerosis onset from 1920 to 2022: a population-based study in Western Norway Andrea Habbestad Received Received
  450-P The multiple sclerosis prodrome: Rates of physician visits were elevated in the 15 years before a first demyelinating event and differed by age and sex; an international matched cohort study. Helen Tremlett Received Received
  451-P Chronic infections and malignancy screening in Mexican patients with multiple sclerosis before initiating disease modifying treatments. lizeth zertuche Received Received
  453-P Clinical outcomes and treatment strategy of multiple sclerosis in China: Results from a real-world cross-sectional survey Wenhao Wang Received Received
  460-P The Impact of Menopause on the Clinical Trajectory of Multiple Sclerosis Francesca Bridge Received Received
  462-P Pregnancy and birth outcomes in MS women : comparison of the RESPONSE cohort to the general French population. Elisabeth Maillart Received Received
  463-P Pregnancy reduces the risk of reaching irreversible EDSS 3 in women with multiple sclerosis, but theres a catch! Vilija Jokubaitis Received Received
  464-P RESPONSE, a French cohort of pregnant women with MS and related disorders and their children until the age of 6. Protocol and baseline characteristics. Sandra Vukusic Received Received
  480-P Relationship Between Socioeconomic Status and Depression in Patients with Multiple Sclerosis Bryn Rubin Received Received
  483-P Clinical trial evidence of quality-of-life effects of disease modifying therapies for multiple sclerosis Perrine Janiaud Received Received
  485-P MS Falls InsightTrack (MS-FIT): Design and Stakeholder Perspectives on a Closed-loop Falls Monitoring and Prevention Application for MS Clinical Practice Valerie Block Received Received
  486-P Evaluating the patients experience after switching from natalizumab intravenous to subcutaneous administration. Analysis of a case series Jose Meca Lallana Received Received
  489-P Risk of Relapse and Sustained Disability Progression in People with MS during the COVID-19 Pandemic Ethan Huson Received Received
  490-P The socio-economic burden of AQP4-antibody seropositive NMOSD: a nationwide registry-based study Viktoria Papp Received Received
  494-P Comorbidity in the aging population with multiple sclerosis -- A nationwide cross-sectional study Rolf Holm Received Received
  496-P Mediterranean Diet is Associated with Cognition in Multiple Sclerosis Ilana Katz Sand Received Received
  502-P Axonal damage in early MS lesions and white matter correlate with neurofilament light chains in serum Imke Metz Received Received
  510-P Pathogenic cerebrospinal fluid antibodies in oligoclonal band-negative primary progressive MS patients Jamie Wong Received Received
  519-P A single cell multi-omics map of cell type specific mechanistic drivers of multiple sclerosis lesions Maria Louise Elkjr Received Received
  527-P SARS-CoV-2 mRNA vaccination affects antibody and cellular immune responses after B-cell depletion therapies Erin Longbrake Received Received
  530-P Cervical lymph nodes in patients with multiple sclerosis show an overrepresentation of memory B cells and a disturbed germinal center reaction Sini Laakso Received Received
  536-P Spatial analysis of lymph nodes show increased follicular T cells in multiple sclerosis patients Joona Sarkkinen Received Received
  538-P Expanded T lymphocyte clones in the cerebrospinal fluid of multiple sclerosis patients are specific for autologous Epstein-Barr virus infected B lymphocytes. John Lindsey Received Received
  548-P In vitro infection of CNS-derived cells with Epstein-Barr virus using a B-cell transfer method Roberto Alfonso Received Received
  551-P Inverse association between mediterranean diet and risk of multiple sclerosis Lars Alfredsson Received Received
  571-P Increased white matter disconnectivity and inflammation in multiple sclerosis patients with paramagnetic rim lesions Ceren Tozlu Received Received
  574-P Choroid plexus volume and slowly expanding lesions as inflammatory markers in relapsing multiple sclerosis. Muhammad Raghib Received Received
  575-P Choroid plexus volume correlates with advanced MRI metrics in relapsing multiple sclerosis. Muhammad Raghib Received Received
  577-P Inclusion of attention gates in a 3D CNN model improves the performance in new T2 lesion quantification Sergi Valverde Received Received
  579-P Accumulation of iron-rim lesions correlates with change in cognition in early Multiple Sclerosis Radu Tanasescu Received Received
  584-P Thalamus-derived Radiomic Features to Predict Symbol Digit Modalities Test Results in MS. Korhan Buyukturkoglu Received Received
  599-P The value of magnetic resonance imaging of the optic nerve for the diagnosis of multiple sclerosis in patients with acute optic neuritis. Gorm Pihl-Jensen Received Received
  600-P Early neurofilament light chain levels are correlated with brain atrophy up to 4 years in dimethyl-fumarate treated patients with relapsing remitting multiple sclerosis Tobias Sejbaek Received Received
  613-P Visible T2 thin cortical lines on MRI may reflect cortical damage in MS Mohammad Aboulwafa Received Received
  615-P Neurodegeneration may occur without evidence of clinical or neuroinflammatory relapse in recently-diagnosed relapsing-remitting multiple sclerosis Rozanna Meijboom Received Received
  634-P Plasma IgG Aggregates as Biomarkers for MS and for Diagnosing SPMS Xiaoli Yu Received Received
  635-P Aberrant PD-1/PD-L1 expression in immune cell subsets and elevated soluble PD-L1 levels in mutiple sclerosis patients correlate with disease activity and disability Thanos Tsaktanis Received Received
  638-P Trends, Features, and Utility of Testing Myelin Oligodendrocyte Glycoprotein Autoantibodies in CSF Jodie Burton Received Received
  641-P Disease Activity Score and Disease Pathway Scores Measured Using the MSDA Test are Significantly Reduced Prior to the Week 48 Dose for Patients Treated with Ublituximab in the Phase 3 ULTIMATE I and II Studies Melissa Karr Received Received
  647-P Large-scale cerebrospinal fluid proteomics of more than 4500 patients for biomarker discovery in multiple sclerosis Christine Makarov Received Received
  650-P Immune cell surface markers reflect cognitive impairment in patients with MS, NMOSD and MOGAD Kimberly Koerbel Received Received
  660-P Leveraging untargeted metabolomic profiling to discern biological processes dysregulated by recent relapse activity in multiple sclerosis Farren Briggs Received Received
  663-P Stool glial fibrillary acidic protein is a biomarker of progressive multiple sclerosis and predicts disease worsening Luke Schwerdtfeger Received Received
  664-P Retinal ganglion cell function in AQP4 and MOG Optic Neuritis Katharina Messias Received Received
  672-P Improving Precision Medicine for Multiple Sclerosis with Uncertainty-Aware Causal Models Jean-Pierre Falet Received Received
  698-P Effective depletion of CD20 lymphocytes after the first application of ofatumumab Franz Felix Konen Received Received
  700-P Inhibiting CEMIP Activity in Demyelinating Lesions Promotes Functional Remyelination Larry Sherman Received Received
  703-P The neuroprotective potential of mesenchymal stem cells from bone marrow and human exfoliated deciduous teeth in murine models of multiple sclerosis Torbjrn Krkenes Received Received
  708-P Reduction in Absolute Lymphocyte Count in Patients Transitioning from Dimethyl Fumarate to Diroximel Fumarate. Kyle Smoot Received Received
  709-P Long-term Effect of Ofatumumab on Serum Immunoglobulin Levels in Patients With Relapsing Multiple Sclerosis Amitha Singh Thakur Received Received
  717-P Prediction of gammaglobulin decrease during rituximab treatment in MS Sandra Kallin Received Received
  735-P New methods to estimate the effect of disease modifying treatment on disability in multiple sclerosis in open observational cohort studies. Melinda Magyari Received Received
  736-P Descriptive demographic and clinical characteristics for Alemtuzumab treated patients with MS vs. other disease modifying therapies treated patients with MS: Preliminary results of a feasibility analysis Jian-Yu E Received Received
  742-P A Retrospective Analysis of Natalizumab First-line Versus Later-line Use in Multiple Sclerosis Treatment: Evidence from a US Claims Database Study Mattia Gianinazzi Received Received
  746-P Characterizing up to 2 years of ofatumumab onboarding and utilization among real-world relapsing multiple sclerosis patients in Australia - the EAFToS Secondary Use of Data Study Morag Nelson Received Received
  755-P Employing Novel Indirect Treatment Comparison Methodologies to Differentiate the Efficacy of Ofatumumab and Other High Efficacy Therapies versus Orally Administered Disease Modifying Therapies for Relapsing Multiple Sclerosis Morag Nelson Received Received
  760-P Grey Matter Structural Changes and their Correlation with Tremor Severity in Multiple Sclerosis: A Case-Control Study Ahmed Bayoumi Received Received
  761-P When does multiple sclerosis (MS) start? Findings from an international pediatric-onset MS population suggests higher than expected health care use from birth Helen Tremlett Received Received
  766-P Increased Aerobic Glycolysis in Normal Appearing White Matter of Multiple Sclerosis Patients Matthew Brier Received Received
  768-P Analysis of the Global Landscape of Multiple Sclerosis Research Bruce Bebo Received Received
  777-P Increased Sleep Fragmentation and Circadian Irregularity are Associated with Cognitive Impairment in Multiple Sclerosis. Jiyeon Son Received Received
  780-P The Role of Surveillance MRI in Paediatric-onset MOGAD and NMOSD: A Retrospective Cohort Study Paridhi Shah Received Received
  784-P OLIKOS Study: 6-Month Interim Efficacy and Safety in Patients With Relapsing Multiple Sclerosis Who Switched to Subcutaneous Ofatumumab From Intravenous Anti-CD20 Therapies Erin Moskal Received Received
Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
12:22
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

 

9th Joint ECTRIMS-ACTRIMS meeting

 

11–13 October 2023 Milan
FAQs
Virtual Poster Gallery
Search and consult posters online
in an exclusive section
for each poster
    ACTIVE FROM 11/10/2023 TO 11/10/2023
Poster
Gallery
Upload
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
                  




PosterSessionOnline
Logo Draft
 
Logo Cert